NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/24/2026
Back to search
Official data from USPTO
VIVIDION THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VIVIDION THERAPEUTICS
ST13
US500000098853803Class
5, 41, 42, 44
Filing
98853803
Registration
8148229
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
02/25/2026
Trademark type
Word
Nice classes
5, 41, 42, 44
Filing date
11/14/2024
Registration date
02/24/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/24/2026
Last transaction
02/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2023-07-00
First use in commerce
2023-07-00
Drawing code
4
Owner type
03
Owner location
San Diego, CA, US
Examiner
RICKS, AUDREY NICOLE
Law office
O20
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Vividion Therapeutics, Inc.
Representatives
Joel E. Tragesser Quarles & Brady LLP
Technical classification
Nice Classes
Class 5Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of cancer
Class 41
Providing a website featuring blogs and non-downloadable publications in the nature of articles in the fields of cancerimmune disorderspharmaceuticalsproteomics; Providing a website featuring non-downloadable publications in the nature of articles in the fields of cancerimmune disorderspharmaceuticalsproteomics
Class 42
Providing medical informationinformation about medical research in the fields of cancerimmune disorderspharmaceuticalsproteomics; Providing a website featuring informationmedical research in the fields of cancerimmune disorderspharmaceuticalsproteomics
Class 44
Providing medical information in the fields of cancerimmune disorderspharmaceuticalsproteomics; Providing a web site featuring medical information; Providing a website featuring medical information in the fields of cancerimmune disorderspharmaceuticalsproteomics
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/24/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/06/2026
PUBO
PUBLISHED FOR OPPOSITION
01/06/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/31/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/10/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
08/11/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
08/11/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/12/2025
GNRT
NON-FINAL ACTION E-MAILED
05/12/2025
CNRT
NON-FINAL ACTION WRITTEN
05/12/2025
DOCK
ASSIGNED TO EXAMINER
05/09/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/26/2025
NWAP
NEW APPLICATION ENTERED
11/14/2024
Continuous trademark protection
Get notified about every new filing that threatens VIVIDION THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.